Loading company…
Parthenon Therapeutics develops antibody therapies targeting the tumor microenvironment.
Founded in 2019 and based in Cambridge, US, Parthenon Therapeutics is developing PRTH-101, a monoclonal antibody targeting DDR1. The product is in a Phase 1c trial for patients with immune checkpoint inhibitor-refractory thymic carcinoma. In August 2021, the company raised USD 40 mn in Series A funding co-led by Northpond Ventures and Pfizer Venture Investments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in